ImmunoGenes to develop antibody-producing sheep
Budapest/Zug/Edinburgh – Swiss/Hungarian antibody specialist ImmunoGenes has inked a collaboration and license agreement with the Scottish Roslin Institute to develop specialised sheep that use ImmunoGenes’ proprietary technology to produce high concentrations of polyclonal antibodies. Under the partnership, The Roslin Institute will create transgenic sheep for the neonatal Fc receptor for IgG (FcRn). ImmunoGenes has demonstrated that this receptor augments the immune response, resulting in a significant increase in the production of antibodies from a single animal. ImmunoGenes has used its proprietary FcRn technology to significantly increase yields of polyclonal antibodies in mice and rabbits. The collaboration with The Roslin Institute is intended to demonstrate that ImmunoGenes’ FcRn technology can be used in sheep to produce significantly higher levels of polyclonal antibodies than can be produced by conventional animals. In addition to the scientific collaboration, the agreement also grants ImmunoGenes an exclusive license to commercialise the resulting transgenic animals, which allow sufficient quantities of antibodies to be harvested far quicker than with standard techniques.